Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer

58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.03.072 ◽

2021 ◽

Vol 32 ◽

pp. S45

Author(s):

X. Guan ◽

H-C. Li ◽

Q-J. Chen ◽

B. Hua ◽

J-J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1909478 ◽

2021 ◽

pp. 1-10

Author(s):

Carlos Henrique Botelho ◽

Maria Del Pilar Estevez-Diz ◽

Alessandro Gonçalves Campolina

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Risk Of Recurrence ◽

Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China

Clinical Drug Investigation ◽

10.1007/s40261-019-00842-0 ◽

2019 ◽

Vol 40 (1) ◽

pp. 25-32 ◽

Cited By ~ 2

Author(s):

Xiaoxia Wei ◽

Hong Sun ◽

Jie Zhuang ◽

Xiuhua Weng ◽

Bin Zheng ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Pharmacogenetic Testing ◽

Effectiveness Analysis ◽

Estrogen Receptor Positive

Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective

PLoS ONE ◽

10.1371/journal.pone.0172731 ◽

2017 ◽

Vol 12 (3) ◽

pp. e0172731 ◽

Cited By ~ 6

Author(s):

Caroline S. Clarke ◽

Rachael M. Hunter ◽

Ian Shemilt ◽

Victoria Serra-Sastre

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Trastuzumab ◽

Effectiveness Analysis ◽

Payer Perspective

Cost Effectiveness Analysis of Targeted Intraoperative Radiotherapy Alone (TARGIT-A) in Early Breast Cancer Patients

Value in Health ◽

10.1016/j.jval.2014.08.2306 ◽

2014 ◽

Vol 17 (7) ◽

pp. A640 ◽

Cited By ~ 3

Author(s):

A. Vaidya ◽

P. Vaidya ◽

B. Both ◽

C. Brew-Graves ◽

J. Vaidya

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Early Breast Cancer ◽

Intraoperative Radiotherapy ◽

Breast Cancer Patients ◽

Effectiveness Analysis ◽

Radiotherapy Alone

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

Value in Health ◽

10.1016/s1098-3015(10)68918-8 ◽

2007 ◽

Vol 10 (3) ◽

pp. A125 ◽

Cited By ~ 1

Author(s):

E Orlewska ◽

T Pienkowski ◽

K Drosik ◽

M Gyldmark ◽

R Aultman ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Early Breast Cancer ◽

Her2 Positive ◽

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

Clinical Drug Investigation ◽

10.1007/s40261-021-01114-6 ◽

2022 ◽

Author(s):

C. Louwrens Braal ◽

Anne Kleijburg ◽

Agnes Jager ◽

Stijn L. W. Koolen ◽

Ron H. J. Mathijssen ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Therapeutic Drug Monitoring ◽

Early Breast Cancer ◽

Drug Monitoring ◽

Adjuvant Tamoxifen ◽

Therapeutic Drug ◽

Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context

Journal of Breast Cancer ◽

10.4048/jbc.2010.13.3.286 ◽

2010 ◽

Vol 13 (3) ◽

pp. 286 ◽

Cited By ~ 4

Author(s):

Hye-Jae Lee ◽

Tae-Jin Lee ◽

Bong-Min Yang ◽

Junwon Min

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Hormonal Treatments

PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

Value in Health ◽

10.1016/s1098-3015(10)67270-1 ◽

2005 ◽

Vol 8 (6) ◽

pp. A43

Author(s):

J Karnon ◽

TE Delea ◽

NL Papo ◽

V Barghout ◽

SK Thomas ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

The Uk